If you have been reading about GHRH receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-14. Numbers and descriptions here follow the published literature rather than marketing material.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
In early 2022, as a result of the 2022 Russian invasion of Ukraine, the United States and other countries placed the Russian Direct Investment Fund (RDIF) on the list of sanctioned Russian entities and people, significantly reducing Sputnik V's commercial prospects. The Gam-COVID-Vac vaccine itself is available in two forms: frozen (vaccine storage: below −18 °C) and liquid (vaccine storage: from +2 to +8 °C, produced a little). In addition to the main vaccine, vaccines and its derivatives were registered: Gam-COVID-Vac-Lyo (Russian: Гам-КОВИД-Вак-Лио, freeze dried powder version), Sputnik Light (Russian: Спутник Лайт, used for revaccination, as well as vaccination of foreigners in Russia), Gam-COVID-Vac-M (Russian: Гам-КОВИД-Вак-М, for vaccination of adolescents 12–17 years old).
== Use and storage == Soy sauce may be added directly to food and is commonly used as a dipping sauce or used as seasoning in cooking. It is often eaten with rice, noodles, sushi, or sashimi, or mixed with ground wasabi for dipping. Bottles of soy sauce for the purpose of seasoning dishes are common on restaurant tables in many countries. Soy sauce is indefinitely shelf-stable.
a) all columns will be connected in series, forming a single continuous loop; b) typically, between each column there will be provisions for four process streams: incoming feed mixture, exiting purified fast component, exiting purified slow component, and incoming solvent or eluent; and
Nevertheless, Essendon went on to win the 1942 Premiership with Western Australian Wally Buttsworth in irrepressible form at centre half-back. Essendon won the 1942 Premiership by defeating Richmond in the grand final, 19.18 (132) to 11.13 (79). The match was played at Princes Park in front of 49,000 spectators. Essendon lost the 1943 grand final to Richmond by 5 points, finished 3rd in 1944, and dropped to 8th in 1945. After World War II, Essendon enjoyed great success. In the five years immediately after the war, Essendon won three premierships (1946, 1949, 1950) and were runners-up twice (1947, 1948). In 1946, Essendon were clearly the VFL's supreme force, topping the ladder after the home-and-away games and surviving a drawn second semi-final against Collingwood to make it through to the grand final a week later with a score of 10.16 (76) to 8.9 (57). In the grand final against Melbourne, Essendon set a grand final record score of 22.18 (150) to Melbourne 13.9 (87), featuring a 7-goal performance by centre half-forward Gordon Lane. Rover Bill Hutchinson, and defenders Wally Buttsworth, Cec Ruddell and Harold Lambert were among the best players. Essendon lost the 1947 Grand Final to Carlton by a single point despite recording 30 scoring shots to 21. The following year, Essendon tied with Melbourne in the 1948 grand final, kicking 7.27 to Melbourne's 10.9, before losing the replay 13.11 (89) to 7.8 (50).
Sources: en.wikipedia.org
=== Post-RDS-1 === In the subsequent years it became increasingly valuable to gather information on the Soviet nuclear weapons program, which resulted in the development of technologies that could gather airborne particles in a WB-29 weather reconnaissance plane. On September 3, 1949, these particles were used to determine that the detonation time of the first Soviet atomic test, "Joe 1". Further analysis revealed that this bomb was a replicate of the "Fat Man", which was the bomb dropped on Nagasaki in 1945. This investigative methodology combined radiochemistry and other techniques to gather intelligence on nuclear activities. During the 1961 Soviet nuclear tests, most of the Novaya Zemlya shots were likely monitored by RB-47 aircraft flown from RAF Brize Norton and elsewhere. In August, Khrushchev had announced the existence 100 megaton Soviet bomb, ultimately tested as the Tsar Bomba. A JKC-135A was rapidly outfitted to monitor the test, under Operation Speed Light Bravo. Photomutiplier detectors in UV, visibile, and near-IR were used, with multiplication factors above 100 million. Cine and stills cameras were used, with lens resolutions up to 70 mm. One side of the aircraft was scorched. It has been argued that if the Tsar Bomba had been configured to yield 100 megatons instead of the decided 50, that the aircraft would have been destroyed. The United Kingdom worked with the US to monitor Soviet tests. RAF debris collection missions flew from the summer of 1949 from Scotland, Northern Ireland, and Gibraltar, filling the North Atlantic.
Cryogenic cooling of devices and material is usually achieved via the use of liquid nitrogen, liquid helium, or a mechanical cryocooler (which uses high-pressure helium lines). Gifford-McMahon cryocoolers, pulse tube cryocoolers and Stirling cryocoolers are in wide use with selection based on required base temperature and cooling capacity. The most recent development in cryogenics is the use of magnets as regenerators as well as refrigerators. These devices work on the principle known as the magnetocaloric effect.
NASA spin-off technologies are commercial products and services which have been developed with the help of NASA, through research and development contracts, such as Small Business Innovation Research (SBIR) or STTR awards, licensing of NASA patents, use of NASA facilities, technical assistance from NASA personnel, or data from NASA research. Information on new NASA technology that may be useful to industry is available in periodical and website form in "NASA Tech Briefs", while successful examples of commercialization are reported annually in the NASA publication Spinoffs. The publication has documented more than 2,000 technologies over time. In 1979, notable science fiction author Robert A. Heinlein helped bring awareness to the spin-offs when he was asked to appear before Congress after recovering from one of the earliest known vascular bypass operations to correct a blocked artery. In his testimony, reprinted in his 1980 book Expanded Universe, Heinlein claimed that four NASA spin-off technologies made the surgery possible, and that they were only a few from a long list of NASA spin-off technologies from space development. Since 1976, the NASA Technology Transfer Program has connected NASA resources to private industry, referring to the commercial products as spin-offs. Well-known products that NASA claims as spin-offs include memory foam (originally named temper foam), freeze-dried food, firefighting equipment, emergency "space blankets", DustBusters, cochlear implants, LZR Racer swimsuits, and CMOS image sensors.
==== Propagation ==== Tulips spread rapidly across Europe, and more opulent varieties such as double tulips were already known in Europe by the early 17th century. These curiosities fitted well in an age when natural oddities were cherished especially in the Low Lands, France, Germany and England, where the spice trade with the East Indies had made many people wealthy. Nouveaux riches seeking wealthy displays embraced the exotic plant market, especially in the Low Countries where gardens had become fashionable. A craze for bulbs soon grew in France, where in the early 17th century, entire properties were exchanged as payment for a single tulip bulb. The value of the flower gave it an aura of mystique, and numerous publications describing varieties in lavish garden manuals were published, cashing in on the value of the flower. An export business was built up in France, supplying buyers in the Low Lands, Germany and England. The trade drifted slowly from the French to the Dutch.
== Teaching == The department is heavily involved in teaching across the medical and veterinary sciences as well as the natural sciences. Over 450 undergraduate students are trained each year in the 2nd year Biology of Disease course, taught to a cohort of medical, veterinary and natural sciences students in their second year. Further third year teaching takes the form of the Part II Pathology course which again features a mixed cohort of approximately 90 students. Finally, specific clinical teaching is also provided in collaboration with the clinical school.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.